These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23774797)

  • 1. Antiplatelet drugs are a risk factor for esophageal mucosal injury.
    Sugimoto M; Uotani T; Nishino M; Yamade M; Sahara S; Yamada T; Osawa S; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T
    Digestion; 2013; 87(4):281-9. PubMed ID: 23774797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
    Sugimoto M; Nishino M; Kodaira C; Yamade M; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
    J Clin Pharmacol; 2010 Mar; 50(3):320-30. PubMed ID: 19940233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.
    Uotani T; Sugimoto M; Nishino M; Kodaira C; Yamade M; Sahara S; Yamada T; Osawa S; Sugimoto K; Tanaka T; Umemura K; Watanabe H; Miyajima H; Furuta T
    Clin Gastroenterol Hepatol; 2012 Aug; 10(8):879-885.e2. PubMed ID: 22542748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
    Sugimoto M; Nishino M; Kodaira C; Yamade M; Uotani T; Ikuma M; Furuta T
    Digestion; 2012; 85(1):9-17. PubMed ID: 22122999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel.
    Tozawa K; Oshima T; Okugawa T; Ogawa T; Ohda Y; Tomita T; Hida N; Fukui H; Hori K; Watari J; Nakamura S; Miwa H
    Dig Dis Sci; 2014 Aug; 59(8):1885-90. PubMed ID: 24659236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dilemma between gastroprotection and cardiovascular prevention].
    Venerito M; Kandulski A; Malfertheiner P
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2193-8. PubMed ID: 20979006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
    Uotani T; Sugimoto M; Nishino M; Ichikawa H; Sahara S; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T
    J Clin Pharmacol; 2014 Aug; 54(8):858-64. PubMed ID: 24615745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
    Hsu PI; Lai KH; Liu CP
    Gastroenterology; 2011 Mar; 140(3):791-8. PubMed ID: 21144850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes].
    Lu FM; Tong ZL; Mao YM; Wu DY; Xu J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Aug; 29(4):478-81. PubMed ID: 22875511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of gastric mucosal injury severity with platelet function and gastric pH during low-dose aspirin treatment.
    Nishino M; Sugimoto M; Uotani T; Yamade M; Sahara S; Ichikawa H; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T
    Digestion; 2013; 88(2):79-86. PubMed ID: 23941821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors and clopidogrel.
    Gaglia MA; Waksman R
    Cardiovasc Ther; 2010 Jun; 28(3):169-76. PubMed ID: 20345494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
    El-Halabi MM; Zgheib N; Mansour NM; Malli A; Ghaith OA; Mahfouz R; Alam S; Sharara AI
    J Cardiovasc Pharmacol; 2013 Jul; 62(1):41-9. PubMed ID: 23474843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
    Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
    Tran M; Tafreshi J; Pai RG
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling.
    Johnson DA; Chilton R; Liker HR
    Postgrad Med; 2014 May; 126(3):239-45. PubMed ID: 24918808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.